EVOQUE Transcatheter Tricuspid Valve Replacement Demonstrates Favorable Outcomes
The EVOQUE system has shown promising results in real-world outcomes for Transcatheter Tricuspid Valve Replacement (TTVR), confirming its safety, effectiveness, and quality-of-life gains.
According to the first U.S. real-world data from the STS/ACC TVT Registry, TTVR with the EVOQUE system achieved near-complete elimination of tricuspid regurgitation (TR), significant improvements in functional capacity and quality of life, and low complication rates at 30 days.
The results were presented by Dr. Rahul Sharma of Stanford University at TCT 2025, based on an analysis of early commercial outcomes of the EVOQUE system, which evaluated data from 1,034 patients treated at 82 sites across the United States between February 2024 and March 2025.
Author's summary: EVOQUE system shows promising results in TTVR.